In this multicentre , randomized , open-label , controlled , two-parallel-group , phase II pilot study , patients with AF undergoing electric cardioversion following transoesophageal echocardiography ( TEE ) were randomized to fondaparinux or standard therapy ( UFH plus vitamin K antagonist [ VKA ] ) .